TABLE 1.
Baseline characteristics on day 0 of pregnant women who were assessed by ECG
| Characteristic | Data for treatment group: |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All participants |
AL+a |
ASMQ |
DP |
CHQ |
||||||
| No. of women | Mean (SD) or % (no. of women) | No. of women | Mean (SD) or % (no. of women) | No. of women | Mean (SD) or % (no. of women) | No. of patients | Mean (SD) or % (no. of patients) | No. of patients | Mean (SD) or % (no. of patients) | |
| Age (yrs) | 259b | 25.6 (6.9) | 86 | 25.1 (7.1) | 82 | 25.8 (6.6) | 88 | 25.5 (6.9) | 21 | 25.7 (7.6) |
| Gravidity | 259b | 2.9 (2.0) | 86 | 2.9 (2.2) | 82 | 3.0 (2.1) | 88 | 2.7 (1.8) | 21 | 3.1 (2.0) |
| Height (cm) | 259b | 151.0 (5.6) | 86 | 151.0 (6.1) | 82 | 151.4 (4.9) | 88 | 150.9 (5.9) | 21 | 150.8 (5.2) |
| Smoking | 259b | 20.8% (54) | 86 | 23.3% (20) | 82 | 18.3% (15) | 88 | 19.3% (17) | 21 | 28.6% (6) |
| Gestational age (wks) | 279 | 26.0 (8.3) | 86 | 25.7 (8.6) | 82 | 26.5 (8.9) | 88 | 24.6 (7.8) | 21 | 29.8 (5.3) |
| Weight (kg) | 276 | 52.3 (8.0) | 86 | 51.2 (7.8) | 82 | 53.1 (7.6) | 88 | 51.8 (8.3) | 20 | 55.5 (8.0) |
| Fever (>37.5°C) | 278 | 30.2% (84) | 86 | 33.7% (29) | 82 | 34.1% (28) | 88 | 27.3% (24) | 21 | 14.3% (3) |
| Heart rate (per min) | 273 | 93.6 (16.2) | 84 | 96.2 (17.2) | 80 | 95.6 (16.0) | 88 | 91.0 (15.7) | 19 | 86.8 (12.6) |
| Hematocrit (%) | 279 | 32.4 (3.7) | 86 | 32.3 (3.3) | 82 | 32.8 (4.3) | 88 | 32.3 (3.8) | 21 | 31.9 (2.7) |
| Malaria species infection type | 279 | 86 | 82 | 88 | 21 | |||||
| P. falciparum monoinfection | 28.3% (79) | 30.2% (26) | 35.4% (29) | 25.0% (22) | 0.0% (0) | |||||
| P. vivax monoinfection | 69.5% (194) | 68.6% (59) | 62.2% (51) | 71.6% (63) | 100.0% (21) | |||||
| P. falciparum plus P. vivax | 1.8% (5) | 1.2% (1) | 2.4% (2) | 2.3% (2) | 0.0% (0) | |||||
| Plasmodium malariae monoinfection | 0.4% (1) | 0.0% (0) | 0.0% (0) | 1.1% (1) | 0.0% (0) | |||||
| Asexual parasite load/μl | 279 | 10,262.9 (21,418.2) | 86 | 10,304.4 (19,886.1) | 82 | 13,090.7 (25,924.4) | 88 | 9,621.2 (20,502.7) | 21 | 2,400.8 (6,403.9) |
| Presence of gametocyte | 279 | 48.4% (135) | 86 | 47.7% (41) | 82 | 40.2% (33) | 88 | 52.3% (46) | 21 | 66.7% (14) |
| Anorexia | 279 | 38.0% (106) | 86 | 38.4% (33) | 82 | 40.2% (33) | 88 | 37.5% (33) | 21 | 23.8% (5) |
| Nausea | 279 | 31.5% (88) | 86 | 36.0% (31) | 82 | 37.8% (31) | 88 | 29.5% (26) | 21 | 0.0% (0) |
| Vomiting | 279 | 16.1% (45) | 86 | 12.8% (11) | 82 | 24.4% (20) | 88 | 14.8% (13) | 21 | 0.0% (0) |
| Dizziness | 279 | 63.1% (176) | 86 | 64.0% (55) | 82 | 61.0% (50) | 88 | 68.2% (60) | 21 | 47.6% (10) |
| Diarrhea | 279 | 2.2% (6) | 86 | 3.5% (3) | 82 | 0.0% (0) | 88 | 3.4% (3) | 21 | 0.0% (0) |
| Palpitation | 279 | 31.5% (88) | 86 | 33.7% (29) | 82 | 30.5% (25) | 88 | 37.5% (33) | 21 | 0.0% (0) |
| Fatigue | 279 | 53.8% (150) | 86 | 50.0% (43) | 82 | 56.1% (46) | 88 | 55.7% (49) | 21 | 47.6% (10) |
a
AL+, extended artemether-lumefantrine; ASMQ, artesunate-mefloquine; CHQ, chloroquine; DP, dihydroartemisinin-piperaquine.
b
Only the first episode was included.